Varun Prabhu, Ph.D.
Vice President, Research and Development
Varun manages translational medicine activities including mechanism of action and pre-clinical efficacy studies, GLP toxicology studies, IND submission, Phase I and Phase II clinical protocol development, clinical biomarker development, CRO relationships, academic collaborations and grant submissions. He has worked collaboratively with Oncoceutics since 2012, as a researcher in the lab of scientific founder Dr. Wafik El-Deiry. Dr. Prabhu was the first to demonstrate the anti-cancer stem cell efficacy of ONC201 and is co-inventor on patents for the use of imipridone small molecules for targeting GPCRs and treating gliomas. He completed his B.S. in Pharmaceutical Sciences from the Institute of Chemical Technology in India, received a M.S. in Biotechnology from the University at Buffalo, SUNY and earned a Ph.D. in Molecular Medicine from Pennsylvania State University. He has previously held research positions at the Roswell Park Cancer Institute, the Fox Chase Cancer Center, OncoMed Pharmaceuticals and has co-authored several peer-reviewed publications. He has received awards for research and leadership including the Penn State Alumni Association Dissertation Award, an Innovation Award from MedImmune and was featured by the Philadelphia business journal among young executives in life science.